Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Acuity Inc. has stabilised somewhat since the post-earnings selloff, but the analyst community is still trimming targets and the stock remains down 10% over the past month.
The short side has quieted relative to the flurry described in last week's note. Short interest edged down roughly 0.7% over the past week to 3.5% of the free float, around 1.05 million shares. That is a partial reversal of the rebuild that ran through late September, though the one-month trend is still up about 4.7%. Borrow availability is exceptionally loose, with 21 million shares available against just over 1 million borrowed, suggesting no squeeze mechanics are in play. The cost to borrow is low at 0.43%, up about 42% on the week but still barely above zero in absolute terms. Options positioning tells a mildly cautious story: the put/call ratio is running at 0.80, modestly above its 20-day average of 0.71, about 1.2 standard deviations elevated. That is not a dramatic hedge, but it is directionally consistent with the broader defensive tone since the earnings print.
The more active story remains on the analyst side, and the direction has not improved. Oppenheimer's Christopher Glynn cut his price target from $440 to $415 on October 8, maintaining his Outperform rating. Baird trimmed again, moving from $360 to $348 just days earlier, also keeping Neutral. Those follow William Blair's outright downgrade to Market Perform on September 28. The consensus mean target now sits at $375, about 25% above the current price of $300.42. That gap is wide, but recent analyst movement is one-directional: the bulls are shaving targets and the bears are gaining company. Morgan Stanley holds the most constructive position with an Overweight and a $410 target set in early July, while Goldman Sachs is at Neutral with a $358 target from June. The EV/EBITDA multiple has drifted up slightly on the week to 9.3x, but the trailing PE has compressed to 13.2x over the past month, reflecting both the price decline and earnings dynamics. Factor scores offer partial support: EPS momentum over 30 days ranks in the 91st percentile and the EV/EBIT value score ranks 71st, but the 12-month forward earnings growth rank is only in the 30th percentile, and analyst recommendation differentiation sits at just the 1st percentile, meaning the Street is unusually clustered rather than divergent.
The attention signal in the alt data is worth a brief note. Wikipedia page views for Acuity are running about 2.3 standard deviations above the company's own 90-day average as of late September. Neither of the two datasets tracked for the company has been measured to lead reported financials, so this is retail attention rather than a fundamental read. The next earnings event is scheduled for January 8, 2027, leaving 92 days before the next print.
On the ownership side, FMR (Fidelity) reported 10.9% of shares held as of September 30, with a substantial addition of roughly 962,000 shares in the latest period. BlackRock and State Street made minor additions. The activist register carries only passive 13G holders, and no 13D filings have been made. Those stakes are as last disclosed around the 5% threshold and holders can fall below without a further filing.
The picture heading into the next quarter is one of steady selling pressure at the analyst level, modest but non-alarming short positioning, and a stock trading about 25% below the consensus target after a month in which it has given back 10%. What to watch is whether any of the remaining Outperform holders follow Oppenheimer in narrowing their targets toward the current price, and whether short interest resumes the rebuild that characterised the first week after earnings.
See the live data behind this article on ORTEX.
Open AYI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
